Mgr. Zuzana Jašková, Ph.D.
Researcher, Biobank and CELSPAC Laboratories
Correspondence Address:
Kotlářská 267/2, 611 37 Brno
Office: bldg. D29/1S118
Kamenice 753/5
625 00 Brno
Phone: | +420 549 49 4793 |
---|---|
E‑mail: |
Inactive employment status
Total number of publications: 18
2020
-
PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells
Leukemia Research, year: 2020, volume: 89, edition: FEB 2020, DOI
2019
-
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
Haematologica, year: 2019, volume: 104, edition: 12, DOI
-
Potenciál inhibice proteinu checkpoint kinase 1 u chronické lymfocytární leukémie s mutacemi v genu TP53.
Year: 2019, type: Conference abstract
2018
-
Inovativní inhibitor proteinu CHK1 indukuje apoptózu u buněk chronické lymfocytární leukémie s mutacemi v genu TP53
Year: 2018, type: Conference abstract
-
Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations
Year: 2018, type: Conference abstract
2017
2016
-
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells
Oncotarget, year: 2016, volume: 7, edition: 38, DOI
-
Pro-apoptotic effects of prima-1met correlate with Noxa gene induction in chronic lymphocytic leukemia cells
Year: 2016, type: Conference abstract
2015
-
Elimination of mutated p53 protein and induction of p53 downstream genes in chronic lymphocytic leukemia cells using prima-1met.
Year: 2015, type: Conference abstract
-
NOD/SCID IL2R gamma-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines
Leukemia & Lymphoma, year: 2015, volume: 56, edition: 11, DOI